The Rubicon Research IPO has caught market attention with a swift and strong subscription on the second day of bidding, reflecting robust interest from investors across categories. Here’s a detailed look at the IPO, its subscription numbers, and the company’s operations.
Market Performance
Rubicon Research’s initial public offering (IPO) received overwhelming bids on October 10, the second day of the issue. According to NSE data:
- Total shares bid: 1,91,32,230
- Total shares on offer: 1,64,55,670
This indicates that the IPO was fully subscribed well before its scheduled close on October 13.
Investor category-wise response shows:
- Retail Individual Investors (RIIs): 3.2 times subscription
- Non-Institutional Investors: 136% subscription
- Qualified Institutional Buyers (QIBs): 38% subscription
Additionally, Rubicon Research has mobilized Rs 619 crore from anchor investors, further reflecting confidence in the offering.
Rubicon Research IPO Details
The IPO is structured as a combination of fresh issue and Offer For Sale (OFS):
- Total IPO size: Rs 1,377.5 crore
- Fresh issue of equity shares: Rs 500 crore
- OFS by promoters (General Atlantic Singapore RR Pte Ltd): Rs 877.5 crore
- Price band: Rs 461–485 per share
Post-IPO, General Atlantic’s stake is expected to reduce to just over 35%.
Anchor Investors’ Participation
Kotak Mutual Fund and Motilal Mutual Fund have together invested approximately Rs 169 crore in the company.
- Shares transferred by General Atlantic: 34.86 lakh equity shares
- Percentage of stake: 2.25%
- Transaction value: Rs 169 crore at Rs 484.47 per share
Other promoters include Pratibha Pilgaonkar, Sudhir D Pilgaonkar, Parag S Sancheti, Surabhi P Sancheti, and Sumant S Pilgaonkar.
Use of IPO Proceeds
Rubicon Research plans to utilize the fresh issue proceeds of Rs 310 crore strategically:
- Debt repayment: Major portion allocated
- Inorganic growth: Including acquisitions
- Strategic initiatives and corporate purposes: Remaining funds
This financial planning aims to strengthen the company’s balance sheet while supporting expansion.
Company Overview
Rubicon Research is a pharmaceutical formulation company with a strong focus on R&D and innovation. Key highlights of its operations include:
- Product portfolio: Speciality products and drug-device combination products targeting regulated markets, especially the US
- Recent acquisition: Alkem Laboratories’ formulations facility in Pithampur, Madhya Pradesh, for Rs 149 crore
- Manufacturing & R&D footprint:
- Two US FDA-inspected R&D facilities: India and Canada
- Two manufacturing plants in India with accreditations from USFDA, Maharashtra FDA (WHO-GMP), and Health Canada
The company continues to expand both its product pipeline and manufacturing capabilities, positioning itself as a growing player in the pharmaceutical sector.
Summary
Rubicon Research’s IPO has attracted strong investor interest from all categories, with retail investors leading the charge. The mix of fresh equity issuance and promoter stake sale, along with strategic allocation of funds for debt repayment and expansion, highlights a well-planned public offering.
With its robust focus on R&D, regulated markets, and strategic acquisitions, Rubicon Research is on a trajectory of growth, backed by significant investor confidence as reflected in the IPO subscription.
